[{"address1": "1210-1220 Washington St.", "address2": "Suite 210", "city": "Newton", "state": "MA", "zip": "02465", "country": "United States", "phone": "617 344 4190", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1047590, "exercisedValue": 0, "unexercisedValue": 1034567}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 56, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 730785, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2024, "totalPay": 703157, "exercisedValue": 0, "unexercisedValue": 254161}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 65, "title": "Chief Operating Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1751328000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.61, "open": 1.6, "dayLow": 1.55, "dayHigh": 1.61, "regularMarketPreviousClose": 1.61, "regularMarketOpen": 1.6, "regularMarketDayLow": 1.55, "regularMarketDayHigh": 1.61, "payoutRatio": 0.0, "beta": 0.111, "forwardPE": -1.0261438, "volume": 164265, "regularMarketVolume": 164265, "averageVolume": 439554, "averageVolume10days": 782120, "averageDailyVolume10Day": 782120, "bid": 1.55, "ask": 1.6, "bidSize": 5, "askSize": 5, "marketCap": 95100240, "fiftyTwoWeekLow": 0.855, "fiftyTwoWeekHigh": 3.6, "fiftyDayAverage": 1.2104, "twoHundredDayAverage": 1.608345, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -24267722, "profitMargins": 0.0, "floatShares": 32929531, "sharesOutstanding": 60573400, "sharesShort": 1505384, "sharesShortPriorMonth": 2677418, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0249, "heldPercentInsiders": 0.11457, "heldPercentInstitutions": 0.72273004, "shortRatio": 1.87, "shortPercentOfFloat": 0.0335, "impliedSharesOutstanding": 60573400, "bookValue": 2.567, "priceToBook": 0.6116089, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -116252000, "trailingEps": -1.94, "forwardEps": -1.53, "enterpriseToEbitda": 0.192, "52WeekChange": -0.5227964, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 1.57, "targetHighPrice": 11.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.8, "targetMedianPrice": 10.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 149148000, "totalCashPerShare": 2.462, "ebitda": -126551000, "totalDebt": 29780000, "quickRatio": 7.758, "currentRatio": 8.022, "debtToEquity": 19.149, "returnOnAssets": -0.31312, "returnOnEquity": -0.55682, "grossProfits": -106615000, "freeCashflow": -63624000, "operatingCashflow": -102477000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ABOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Acumen Pharmaceuticals, Inc.", "exchange": "NMS", "messageBoardId": "finmb_8539521", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1753479902, "regularMarketTime": 1753473601, "regularMarketChangePercent": -2.48447, "regularMarketPrice": 1.57, "shortName": "Acumen Pharmaceuticals, Inc.", "marketState": "CLOSED", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1625146200000, "postMarketChangePercent": -0.63694966, "postMarketPrice": 1.56, "postMarketChange": -0.01000011, "regularMarketChange": -0.04, "regularMarketDayRange": "1.55 - 1.61", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 439554, "fiftyTwoWeekLowChange": 0.71500003, "fiftyTwoWeekLowChangePercent": 0.83625734, "fiftyTwoWeekRange": "0.855 - 3.6", "fiftyTwoWeekHighChange": -2.0299997, "fiftyTwoWeekHighChangePercent": -0.56388885, "fiftyTwoWeekChangePercent": -52.27964, "earningsTimestamp": 1747134003, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1755261000, "earningsCallTimestampStart": 1747137600, "earningsCallTimestampEnd": 1747137600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.94, "epsForward": -1.53, "epsCurrentYear": -1.97342, "priceEpsCurrentYear": -0.7955732, "fiftyDayAverageChange": 0.35960007, "fiftyDayAverageChangePercent": 0.29709193, "twoHundredDayAverageChange": -0.03834498, "twoHundredDayAverageChangePercent": -0.023841264, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-01", "averageAnalystRating": "1.0 - Strong Buy", "displayName": "Acumen Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]